Precision BioSciences Inc (FRA:PBS0)
€ 9.85 -0.25 (-2.48%) Market Cap: 65.13 Mil Enterprise Value: -34.23 Mil PE Ratio: 0 PB Ratio: 1.88 GF Score: 54/100

Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

Apr 03, 2023 / 07:20PM GMT
Release Date Price: €21 (+4.60%)
Robert Finke
Guggenheim - Analyst

Good afternoon. Thank you all for joining the 5th Annual Guggenheim Genomic Medicines and Rare Disease Conference. I am Robert. I'm one of the analysts representing the Guggenheim therapeutics team. Today, we are thankful to host Precision BioSciences' Chief Executive, Michael Amoroso.

Michael Amoroso
Precision BioSciences, Inc. - President & CEO

Thank you.

Robert Finke
Guggenheim - Analyst

And Co-founder and Chief Science Officer, Derek Jantz. Thank you both for joining us.

And, Michael, I'd like to hand it over to you for an introduction to the company.

Michael Amoroso
Precision BioSciences, Inc. - President & CEO

Sure. Well, Robert and to the Guggenheim team, thank you for having us. Precision BioSciences, we are a group out of Durham, North Carolina. We are premier gene-editing group, genomic editing based on the platform of -- that this man, to my left, helped co-create known as the ARCUS proprietary platform.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot